Literature DB >> 15645353

Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases.

Luke Bennetto1, April Totham, Pat Healy, Edwin Massey, Neil Scolding.   

Abstract

The standard therapy for episodes of severe acute inflammatory demyelinating disease of the central nervous system is high dose intravenous corticosteroids. A small proportion of patients fail to improve with this regime and their prognosis can become grave. A recent sham controlled double blind crossover trial in this group of patients demonstrated a significant benefit from plasma exchange. We report six patients with severe acute steroid-insensitive inflammatory demyelinating disease of the central nervous system treated with plasma exchange. We observed a clear improvement in five of these six patients. Whilst complications of plasma exchange occurred these did not outweigh the benefits. Our study supports the use of plasma exchange in severe acute steroid-insensitive inflammatory disease of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15645353     DOI: 10.1007/s00415-004-0588-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange.

Authors:  Imma Pericot; Jordi Río; Alex Rovira; M Dolors Castellà; Mar Tintoré; Xavier Montalban
Journal:  J Neurol       Date:  2003-02       Impact factor: 4.849

Review 2.  Multiple sclerosis in the Japanese population.

Authors:  Jun-ichi Kira
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

3.  Role of plasmapheresis in acute disseminated (postinfectious) encephalomyelitis.

Authors:  R B Stricker; R G Miller; D D Kiprov
Journal:  J Clin Apher       Date:  1992       Impact factor: 2.821

4.  Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.

Authors:  P S Sørensen; B Wanscher; W Szpirt; C V Jensen; M Ravnborg; P Christiansen; K Schreiber; A Nordenbo
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

5.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

6.  The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.

Authors: 
Journal:  Lancet       Date:  1991-02-23       Impact factor: 79.321

7.  Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone.

Authors:  R S Tindall; J E Walker; A L Ehle; L Near; J Rollins; D Becker
Journal:  Neurology       Date:  1982-07       Impact factor: 9.910

8.  Plasma exchange for severe attacks of CNS demyelination: predictors of response.

Authors:  M Keegan; A A Pineda; R L McClelland; C H Darby; M Rodriguez; B G Weinshenker
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

9.  A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis.

Authors:  P A Gordon; D J Carroll; W S Etches; V Jeffrey; L Marsh; B L Morrice; D Olmstead; K G Warren
Journal:  Can J Neurol Sci       Date:  1985-02       Impact factor: 2.104

10.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

View more
  8 in total

1.  Plasmapheresis: are bigger studies necessarily better?

Authors:  Brian Weinshenker
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937

2.  Beneficial plasma exchange response in central nervous system inflammatory demyelination.

Authors:  Setty M Magaña; B Mark Keegan; Brian G Weinshenker; Bradley J Erickson; Sean J Pittock; Vanda A Lennon; Moses Rodriguez; Kristine Thomsen; Stephen Weigand; Jay Mandrekar; Linda Linbo; Claudia F Lucchinetti
Journal:  Arch Neurol       Date:  2011-03-14

3.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

Review 4.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  New insights into neuromyelitis optica.

Authors:  Woojun Kim; Su-Hyun Kim; Ho Jin Kim
Journal:  J Clin Neurol       Date:  2011-09-29       Impact factor: 3.077

Review 6.  [A treatment of neuromyelitis optica (Devic's disease) during pregnancy].

Authors:  Moussa Toudou Daouda; Norlin Samuel Obenda; Hamid Assadeck; Diankanagbe Camara; Fatimata Hassane Djibo
Journal:  Pan Afr Med J       Date:  2016-07-13

7.  Improvement of advanced postvaccinal demyelinating encephalitis due to plasmapheresis.

Authors:  Andreas Rogalewski; Jörg Kraus; Martin Hasselblatt; Christoffer Kraemer; Wolf-Rüdiger Schäbitz
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

8.  Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.

Authors:  Johannes Ehler; Sebastian Koball; Martin Sauer; Steffen Mitzner; Heiko Hickstein; Reiner Benecke; Uwe K Zettl
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.